ADVERTISEMENT

Comments?
Help us improve Portfolio Grader.


Comments?
Help us improve Portfolio Grader.


Blue Chip Growth

Stock Report: "Arena Pharmaceuticals, Inc." (ARNA) Report Updated: Jul 21, 2014 | Print This Page

Get more stock ratings by Louis Navellier

"Arena Pharmaceuticals, Inc." (ARNA)

Rating: Sell Volatility: Moderate
Total Grade: D Industry: Biotechnology
Competitors: LJPC, ANAC, CBPO, RGEN

Stock Analysis

Rating: Monthly View

A
B
C
D
F
July August September October November December January February March April May June

Rating: Weekly View

This Week: D down no change
Last Week: D same no change
Two Weeks Ago: D up no change
service keys

"Arena Pharmaceuticals, Inc."© quotemedia

Company Profile

Arena Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in discovering, developing, and commercializing oral drugs that target G protein-coupled receptors in the therapeutic areas of cardiovascular, central nervous system, inflammatory, and metabolic diseases. The company’s advanced stage drug candidate includes the lorcaserin for the treatment of weight management, including weight loss and maintenance of weight loss. Its product in clinical development comprises APD811, which is under Phase I clinical trial for the treatment of pulmonary arterial hypertension. The company’s preclinical development programs include APD334, an oral treatment for the treatment of autoimmune diseases, including multiple sclerosis and rheumatoid arthritis; and APD371 for the treatment of pain. The company also researches and develops GPR119, a pharmaceutical target for discovering orally available small molecule agonists for the treatment of type 2 diabetes, as well as temanogrel, nelotanserin, and earlier-stage programs. In addition, the company provides manufacturing services. Arena Pharmaceuticals, Inc. was founded in 1997 and is based in San Diego, California.

Recent News: "Arena Pharmaceuticals, Inc."